Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation
出版年份 2020 全文链接
标题
Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation
作者
关键词
-
出版物
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-07-16
DOI
10.1007/s00262-020-02646-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma
- (2018) Jacques Raphael et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma
- (2018) Michal Sarfaty et al. EUROPEAN UROLOGY
- Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
- (2018) Michal Sarfaty et al. EUROPEAN UROLOGY
- An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
- (2018) Jason Shafrin et al. HEALTH POLICY
- Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
- (2018) Martin Reck Immunotherapy
- Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
- (2018) David J. Vaughn et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost–effectiveness analysis
- (2018) Ahmad Tarhini et al. Immunotherapy
- A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
- (2018) Vivek Verma et al. Journal for ImmunoTherapy of Cancer
- CASE STUDY ON AN IPILIMUMAB COST-CONTAINMENT STRATEGY IN AN ITALIAN HOSPITAL
- (2017) Alberto Russi et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma
- (2017) Christine G. Kohn et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2017) Kathryn R Tringale et al. JNCI-Journal of the National Cancer Institute
- Cost‐Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma
- (2017) Mahdi Zargar et al. ONCOLOGIST
- Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆
- (2017) Matthew C. Ward et al. ORAL ONCOLOGY
- Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
- (2017) Min Huang et al. PHARMACOECONOMICS
- Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal
- (2017) Luis Silva Miguel et al. VALUE IN HEALTH
- Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2017) Kathryn R Tringale et al. JNCI-Journal of the National Cancer Institute
- Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States
- (2017) Anna Oh et al. Journal of Managed Care & Specialty Pharmacy
- Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States
- (2017) Jingshu Wang et al. Journal of Managed Care & Specialty Pharmacy
- Effectiveness, toxicity, and economic evaluation of ipilimumab for the treatment of patients with metastatic melanoma in the Spanish outpatient setting
- (2016) Beatriz Guglieri-López et al. ANTI-CANCER DRUGS
- A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing
- (2016) Klazien Matter-Walstra et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia
- (2016) Megan A. Bohensky et al. VALUE IN HEALTH
- Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
- (2016) Min Huang et al. JOURNAL OF MEDICAL ECONOMICS
- Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes
- (2016) Ron Goeree et al. JOURNAL OF MEDICAL ECONOMICS
- Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting
- (2015) Edmond L. Toy et al. CURRENT MEDICAL RESEARCH AND OPINION
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- (2015) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Comparative healthcare costs in patients with metastatic melanoma in the USA
- (2015) Chun-Lan Chang et al. MELANOMA RESEARCH
- The cost of ipilimumab toxicity
- (2015) Nadia Yousaf et al. MELANOMA RESEARCH
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
- (2014) Patti Curl et al. PLoS One
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
- (2013) Don Husereau et al. VALUE IN HEALTH
- Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings
- (2013) Anthony Jarkowski et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
- (2012) O. J. Finn ANNALS OF ONCOLOGY
- Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis
- (2012) Victor Barzey et al. JOURNAL OF MEDICAL ECONOMICS
- Health outcomes in economic evaluation: the QALY and utilities
- (2010) S. J. Whitehead et al. BRITISH MEDICAL BULLETIN
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search